Bristol-Meyers Squibb to pay $19.5 million to settle off-label promotion case

WASHINGTON (Reuters) - Drugmaker Bristol-Meyers Squibb Co will pay $19.5 million to resolve multi-state allegations that it improperly promoted a schizophrenia treatment for uses not approved by the U.S. government, New York Attorney General Eric Schneiderman said on Thursday.